臨床婦人科産科76巻8号

2022年08月発行

今月の臨床 HPVワクチン勧奨再開―いま知りたいことのすべて HPVと子宮頸がん・HPV関連疾患

HPV発がんの機序と感染制御機構

著者： 川名敬¹

所属機関： ¹日本大学医学部産婦人科学系産婦人科学分野

ページ範囲：P.725 - P.731

●HPV16，18型に代表されるハイリスクHPVは，感染した上皮細胞に持続感染していくなかで，感染細胞をがん細胞へと変化させることがある．特に女性の子宮頸部は，組織学的な特異性からがん化しやすく，子宮頸がんは若年発症，かつ発生数が圧倒的に多い．

●HPV感染自体を中和抗体によって予防できるHPVワクチンが，子宮頸がんの発症リスクを減少させることが明らかとなった．

●8年以上続いた日本国内での接種勧奨の差し控えが終了し，さらにその間に接種できなかった女性に対するキャッチアップ接種も時限付きではあるが開始される．この機会を逃さずに利用していきたい．

参考文献

1）Gravitt PE : The known unknowns of HPV natural history, J Clin Invest 121 : 4593-4599, 2011

2）Ho GYF, et al : Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 : 423-428, 1998

3）Insinga RP, et al ; FUTURE Investigators : Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young woman. Cancer Epidemiol Biomarkers Prev 19 : 1585-1594, 2010

4）Bosch FX, et al : Human papillomavirus and cervical cancer ― burden and assessment of causality. J Natl Cancer Inst Monogr 31 : 3-13, 2003

5）Inoue M, et al : The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 16 : 1007-1013, 2006

6）Azuma Y, et al : Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin Oncol 44 : 910-917, 2014

7）Onuki M, et al : Human papillomavirus infections among Japanese women : age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 100 : 1312-1316, 2009

8）Mirkovic J, et al : Carcinogenic HPV infection in the cervical squamo-columnar junction. J Pathol 236 : 265-271, 2015

9）WHO : Latest info on introduction status of HPV vaccines, Monitoring and Surveillance of HPV Vaccination Programmes, 2020.　https://www.who.int/immunization/hpv/monitor/en/

10）Garland SM, et al : Impact and effectiveness of the quadrivalent human papillomavirus vaccine : a systematic review of 10 years of real-world experience. Clin Infect Dis 63 : 519-527, 2016

11）Luostarinen T, et al : Vaccination protects against invasive HPV-associated cancers. Int J Cancer 142 : 2186-2187, 2018

12）Lei J, et al : HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 383 : 1340-1348, 2020

13）Kjaer SK, et al : Real-world effectiveness of Human Papillomavirus vaccination against cervical cancer. J Natl Cancer Inst 113 : 1329-1335, 2021

14）Kjaer SK, et al : Final analysis of a14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. eClinicalMedicine 23 : 100401, 2020

15）Barr E, et al : Impact of a prophylactic quadrivalent human papillomavirus（types 6, 11, 16, 18）L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol 198 : 261.e1-261.e11, 2008

16）Seong J, et al : Status of HPV vaccination among HPV-infected women aged 20-60 years with abnormal cervical cytology in South Korea : a multicenter, retrospective study. J Gynecol Oncol 31 : e4, 2020

17）Centers for Disease Control and Prevention（CDC） : HPV Vaccination Recommendations. 　https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html